Pushpa Publishing House

Journal Menu

Content

Volume 25 (2025)

Volume 24 (2024)

Volume 23 (2023)

Volume 18 (2021)

Volume 17 (2020)

Volume 16 (2019)

Volume 15 (2018)

Volume 14 (2017)

Volume 13 (2016)

Volume 12 (2015)

Volume 11 (2014)

Volume 10 (2013)

Volume 9 (2013)

Volume 8 (2012)

Volume 7 (2012)

Volume 6 (2011)

Volume 5 (2011)

Volume 4 (2010)

Volume 3 (2009)

	Volume 3, Issue 3 Pg 171 - 256 (October 2009)
	Volume 3, Issue 2 Pg 77 - 169 (June 2009)
	Volume 3, Issue 1 Pg 1 - 75 (February 2009)

Volume 2 (2008)

Volume 1 (2007)

-->

JP Journal of Biostatistics

medical treatments. The relative performance of the procedures in the Bayesian framework is discussed when the responses to

treatments

are normally distributed with unknown means

and a common known variance

We notice that when

the formulae for the expected regret function for Procedures 1 and 2 performed by Mady are not equivalent with those of Langenberg and Srinivasan [2]. We found that the reason for this situation is as fallows. Mady expressed the expected regret function in terms of the true difference

while Langenberg and Srinivasan expressed the same function in terms of the absolute difference

That is, we must differentiate between two cases: (i)

(ii)

as the probability of selecting the inferior population has a different formual in each case. This paper will express the expected regret function using Procedures 1 and 2 in terms of the absolute value of the true difference between the treatments

instead of

where

and

are the unknown means of treatments

and

respectively. The consideration of this modification leads to major changes in the results.

JP Journal of Biostatistics
Volume 3, Issue 1, Pages 1 - 15 (February 2009)

BAYESIAN PROCEDURES FOR SELECTING THE BEST POPULATION OF (k + 1) NORMAL POPULATIONS
Afaf M. Mady (Egypt)

Abstract:
Mady [3] introduced two simple procedures for dealing with patients who arrive during the waiting period, caused by the lag, between the trial and treatment stages for designing an optimal clinical trial when a total of N patients with a disease are to be treated with one of